Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study | The BMJ
Several studies suggest single dose of vaccine provides strong protection for people who have recovered from COVID-19 - COVID-19 Immunity Task Force
Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals - The Lancet
Chart: 28 Days Later: The Pfizer/BioNTech Vaccination Process | Statista
Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes | Science
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses | Nature
Vaccines | Free Full-Text | A Peptide-Based Assay Discriminates Individual Antibody Response to the COVID-19 Pfizer/BioNTech mRNA Vaccine
COVID-19 Vaccines and Immunity: How Long Does it Take for the Vaccines to Provide Protection? | Newsroom | Weill Cornell Medicine
How long does it take for the vaccine to be effective? | NHK WORLD-JAPAN News
Single dose of Pfizer vaccine shows signs of success in UK | Financial Times
Pfizer vaccine can give early protection 12 days after one dose - SingHealth
Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study - The Lancet
Care needed' after getting Covid vaccine - BBC News
Pfizer/BioNTech vaccine starts working 10 days after first dose, says FDA | Financial Times
Pfizer Vaccine Immunity Timeline for… | Saint Regis Mohawk Tribe
One Pfizer/BioNTech jab gives '90% immunity' from Covid after 21 days | Vaccines and immunisation | The Guardian
Covid vaccines slash risk of infection, illness and death, UK studies find | Financial Times
Those Who Had COVID-19 May Only Need One Dose of Vaccine | Penn Medicine
Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine - ScienceDirect
Coronavirus vaccination: the most important questions and answers
Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors | Nature Communications
Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12–18 Years — United States, July–December 2021 | MMWR
S.Korea says AstraZeneca, Pfizer COVID-19 vaccines 87% effective after first shot | Reuters
Optimising the COVID-19 vaccination programme for maximum short- term impact
Frontiers | The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines
